Handelsbanken Fonder AB Boosts Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Handelsbanken Fonder AB grew its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 27.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 81,900 shares of the company’s stock after purchasing an additional 17,500 shares during the period. Handelsbanken Fonder AB owned approximately 0.24% of TransMedics Group worth $5,106,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in TMDX. Quarry LP grew its position in TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares during the period. National Bank of Canada FI lifted its stake in TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after buying an additional 262 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after purchasing an additional 316 shares in the last quarter. Hager Investment Management Services LLC purchased a new position in TransMedics Group in the 4th quarter worth approximately $33,000. Finally, Sachetta LLC purchased a new stake in shares of TransMedics Group during the 4th quarter valued at approximately $40,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insider Activity

In other news, insider Tamer I. Khayal sold 1,084 shares of TransMedics Group stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.00% of the company’s stock.

TransMedics Group Price Performance

TMDX stock opened at $71.95 on Monday. The firm has a 50 day moving average of $66.63 and a 200-day moving average of $104.16. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The company has a market cap of $2.41 billion, a price-to-earnings ratio of 76.54 and a beta of 2.12.

Wall Street Analyst Weigh In

Several research firms have recently commented on TMDX. Robert W. Baird reduced their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, February 5th. TD Cowen lowered their target price on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Finally, Canaccord Genuity Group decreased their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, TransMedics Group currently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.